Univariable logistic regression analysis of candidate prognostic markers for PTS
| Variable . | OR . | 95% CI . | P . |
|---|---|---|---|
| 6 wk after DVT | |||
| Complete veno-occlusion (yes, 12; no, 67) | 3.29 | 0.93-11.61 | .064 |
| Central venous catheter (yes, 46; no, 33) | 0.68 | 0.27-1.73 | .42 |
| CloFAL measures | |||
| Maximal amplitude | 1.97 | 0.75-5.19 | .169 |
| AUC60, AU | 1.55 | 0.59-4.07 | .377 |
| FI2, AU | 0.74 | 0.26-2.09 | .566 |
| Inflammatory cytokines | |||
| IL-6, pg/mL | 1.55 | 0.59-4.07 | .377 |
| IL-8, pg/mL | 1.03 | 0.38-2.76 | .954 |
| IL-10, pg/mL | 1.09 | 0.4-2.96 | .86 |
| VEGF-1, pg/mL | 0.94 | 0.35-2.52 | .91 |
| CRP, mg/dL | 0.81 | 0.30-2.24 | .692 |
| SAA, mg/L | 1.37 | 0.51-3.67 | .535 |
| VCAM-1, ng/mL | 0.89 | 0.32-2.46 | .82 |
| ICAM-1, ng/mL | 0.89 | 0.32-2.46 | .82 |
| 3 mo after DVT | |||
| CloFAL measures | |||
| Maximal amplitude (OD) | 0.94 | 0.35-2.52 | .91 |
| AUC60, AU | 1.55 | 0.59-4.07 | .377 |
| FI2, AU | 2.51 | 0.93-6.78 | .071 |
| Inflammatory cytokines | |||
| IL-6, pg/mL | 1.32 | 0.50-3.52 | .574 |
| IL-8, pg/mL | 0.8 | 0.29-2.17 | .655 |
| IL-10, pg/mL | 1.55 | 0.59-4.07 | .377 |
| VEGF-1, pg/mL | 0.94 | 0.35-2.52 | .91 |
| CRP, mg/dL | 1.09 | 0.40-2.95 | .865 |
| SAA, mg/L | 2.33 | 0.87-6.23 | .093 |
| VCAM-1, ng/mL | 1.7 | 0.64-4.49 | .288 |
| ICAM-1, ng/mL | 1.32 | 0.5-3.52 | .574 |
| Variable . | OR . | 95% CI . | P . |
|---|---|---|---|
| 6 wk after DVT | |||
| Complete veno-occlusion (yes, 12; no, 67) | 3.29 | 0.93-11.61 | .064 |
| Central venous catheter (yes, 46; no, 33) | 0.68 | 0.27-1.73 | .42 |
| CloFAL measures | |||
| Maximal amplitude | 1.97 | 0.75-5.19 | .169 |
| AUC60, AU | 1.55 | 0.59-4.07 | .377 |
| FI2, AU | 0.74 | 0.26-2.09 | .566 |
| Inflammatory cytokines | |||
| IL-6, pg/mL | 1.55 | 0.59-4.07 | .377 |
| IL-8, pg/mL | 1.03 | 0.38-2.76 | .954 |
| IL-10, pg/mL | 1.09 | 0.4-2.96 | .86 |
| VEGF-1, pg/mL | 0.94 | 0.35-2.52 | .91 |
| CRP, mg/dL | 0.81 | 0.30-2.24 | .692 |
| SAA, mg/L | 1.37 | 0.51-3.67 | .535 |
| VCAM-1, ng/mL | 0.89 | 0.32-2.46 | .82 |
| ICAM-1, ng/mL | 0.89 | 0.32-2.46 | .82 |
| 3 mo after DVT | |||
| CloFAL measures | |||
| Maximal amplitude (OD) | 0.94 | 0.35-2.52 | .91 |
| AUC60, AU | 1.55 | 0.59-4.07 | .377 |
| FI2, AU | 2.51 | 0.93-6.78 | .071 |
| Inflammatory cytokines | |||
| IL-6, pg/mL | 1.32 | 0.50-3.52 | .574 |
| IL-8, pg/mL | 0.8 | 0.29-2.17 | .655 |
| IL-10, pg/mL | 1.55 | 0.59-4.07 | .377 |
| VEGF-1, pg/mL | 0.94 | 0.35-2.52 | .91 |
| CRP, mg/dL | 1.09 | 0.40-2.95 | .865 |
| SAA, mg/L | 2.33 | 0.87-6.23 | .093 |
| VCAM-1, ng/mL | 1.7 | 0.64-4.49 | .288 |
| ICAM-1, ng/mL | 1.32 | 0.5-3.52 | .574 |
Variables analyzed as upper vs middle plus lower tertiles with the exception of FI2, which was analyzed as lower vs middle plus upper tertiles.
AU, arbitrary units; OD, optical density (405‐630 nm).